#Mabwell
LightNews LightNews
delfoo.bsky.social
Russia's Binnopharm Group is planning on starting the production in Russia of medication for asthma and dermatitis from the Chinese company Mabwell.

www.kommersant.ru/doc/8269315
В России локализуют производство лекарства из Китая от астмы и дерматита
Подробнее на сайте
www.kommersant.ru
December 9, 2025 at 7:02 AM
newsen.bsky.social
Mabwell Secures NMPA Approval for MAIWEIJIAN Expanding Treatment Options#China#Shanghai#Denosumab#Mabwell#MAIWEIJIAN
Mabwell Secures NMPA Approval for MAIWEIJIAN Expanding Treatment Options
Mabwell has received NMPA approval for additional applications of MAIWEIJIAN, enhancing treatment options for bone metastases and multiple myeloma.
third-news.com
May 21, 2026 at 12:14 AM
newsen.bsky.social
Mabwell Announces IND Clearance for Innovative Bispecific Antibody Targeting Hematologic Malignancies#China#Shanghai#Mabwell#T_Cell_Engager #6MW5311
Mabwell Announces IND Clearance for Innovative Bispecific Antibody Targeting Hematologic Malignancies
Mabwell has received IND clearance from China’s NMPA for its groundbreaking bispecific antibody 6MW5311, aimed at treating hematologic cancers.
third-news.com
June 24, 2026 at 12:10 AM
newsen.bsky.social
Mabwell Initiates First Clinical Trial of Novel Cancer Treatment 7MW4911 in the U.S.#China#Shanghai#oncology#Mabwell #7MW4911
Mabwell Initiates First Clinical Trial of Novel Cancer Treatment 7MW4911 in the U.S.
Mabwell has commenced a clinical trial in the U.S. for its groundbreaking antibody-drug conjugate 7MW4911, aimed at treating advanced colorectal cancer.
third-news.com
January 22, 2026 at 2:14 PM
newsen.bsky.social
Mabwell Set to Showcase New Clinical Findings on 9MW2821 at ASCO Annual Meeting in 2026#China#Shanghai#Mabwell #9MW2821#ASCO_Annual_Meeting
Mabwell Set to Showcase New Clinical Findings on 9MW2821 at ASCO Annual Meeting in 2026
Mabwell will present impressive clinical trial data on its ADC 9MW2821 at the 2026 ASCO meeting, focusing on bladder cancer treatments.
third-news.com
May 22, 2026 at 3:37 AM
newsen.bsky.social
Mabwell Showcases Promising Clinical Data on 9MW2821 at ESMO GC 2026#Denmark#Copenhagen#Cervical_Cancer#Mabwell #9MW2821
Mabwell Showcases Promising Clinical Data on 9MW2821 at ESMO GC 2026
Mabwell will present new clinical data on its innovative drug 9MW2821 for cervical cancer at the 2026 ESMO GC Annual Congress in Copenhagen.
third-news.com
April 30, 2026 at 4:36 AM
newsen.bsky.social
Mabwell Unveils Promising Clinical Findings of Nectin-4 ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress#Denmark#Copenhagen#Mabwell#Nectin-4 #9MW2821
Mabwell Unveils Promising Clinical Findings of Nectin-4 ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
At the 2026 ESMO Gynaecological Congress in Copenhagen, Mabwell presented significant clinical trial results for its Nectin-4-targeting ADC 9MW2821, indicating strong potential in cervical cancer treatment.
third-news.com
June 18, 2026 at 4:36 PM
newsen.bsky.social
Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring#China#Shanghai#Mabwell#Anti-IL-11#Pathological_Scarring
Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring
Mabwell marks a milestone with the first dosing in China of its innovative anti-IL-11 antibody, aiming to treat pathological scarring in a Phase II trial.
third-news.com
December 30, 2025 at 2:12 PM
newsen.bsky.social
Mabwell Reports Significant Reduction in COPD Exacerbations with 9MW1911 Antibody in Phase IIa Study#China#Shanghai#Mabwell#COPD #9MW1911
Mabwell Reports Significant Reduction in COPD Exacerbations with 9MW1911 Antibody in Phase IIa Study
Mabwell has reported promising Phase IIa results showing over 40% reduction in severe COPD exacerbations with their anti-ST2 antibody 9MW1911. This breakthrough could revolutionize treatment.
third-news.com
December 1, 2025 at 2:32 PM
newsen.bsky.social
Mabwell Achieves Milestone with NMPA’s Acceptance of IND Application for 6MW5311 Bispecific Antibody#China#Shanghai#bispecific_antibody#Mabwell #6MW5311
Mabwell Achieves Milestone with NMPA’s Acceptance of IND Application for 6MW5311 Bispecific Antibody
Mabwell has reached a significant milestone with the acceptance of its IND application for 6MW5311 bispecific antibody targeted at treating blood cancers. This breakthrough could redefine treatment for patients.
third-news.com
April 16, 2026 at 3:45 AM
newsen.bsky.social
Mabwell Bioscience Partners with Aditum Bio to Launch Kalexo Bio for siRNA Cardiovascular Therapy#China#Shanghai#Mabwell_Bioscience#Aditum_Bio#Kalexo_Bio
Mabwell Bioscience Partners with Aditum Bio to Launch Kalexo Bio for siRNA Cardiovascular Therapy
Mabwell and Aditum Bio have founded Kalexo Bio to develop innovative siRNA therapies targeting cardiovascular disorders, promising new hope for patients.
third-news.com
September 17, 2025 at 12:09 PM
newsen.bsky.social
Mabwell's MAIWEIJIAN Receives NMPA Approval for Biologics License Application#China#Shanghai#Denosumab#Mabwell#MAIWEIJIAN
Mabwell's MAIWEIJIAN Receives NMPA Approval for Biologics License Application
Mabwell has received acceptance for MAIWEIJIAN's supplemental Biologics License Application by NMPA, marking a significant milestone for denosumab in China.
third-news.com
April 16, 2026 at 12:05 AM
newsen.bsky.social
Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials#China#Shanghai#ADC#Mabwell#CDH17
Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials
Mabwell has received IND clearance for its CDH17-targeting ADC 7MW4911 from China's NMPA, aiming for clinical studies in advancing gastrointestinal cancers.
third-news.com
October 14, 2025 at 12:12 PM
newsen.bsky.social
Mabwell's Breakthrough Monoclonal Antibody 9MW3811 Approved for Clinical Trials Targeting Pathological Scarring#China#Shanghai#Mabwell#monoclonal_antibody #9MW3811
Mabwell's Breakthrough Monoclonal Antibody 9MW3811 Approved for Clinical Trials Targeting Pathological Scarring
Mabwell has received approval from NMPA to begin Phase II trials for its innovative anti-IL-11 monoclonal antibody, 9MW3811, targeting pathological scarring.
third-news.com
November 11, 2025 at 2:47 PM
newsen.bsky.social
Mabwell's Strategic Global Expansion with First Overseas Shipment of Denosumab Injection#China#Shanghai#pharmaceuticals#Denosumab#Mabwell
Mabwell's Strategic Global Expansion with First Overseas Shipment of Denosumab Injection
Mabwell has made a significant move by announcing the first overseas shipment of its Denosumab Injection, emphasizing its globalization strategy and market expansion.
third-news.com
December 16, 2025 at 2:55 PM
newsen.bsky.social
Mabwell's 9MW5211 Becomes First Novel Antibody to Receive FDA Clearance for Human Trials#China#Shanghai#FDA_Approval#Mabwell #9MW5211
Mabwell's 9MW5211 Becomes First Novel Antibody to Receive FDA Clearance for Human Trials
Mabwell has received FDA clearance for clinical trials of its innovative antibody 9MW5211 aimed at treating inflammatory bowel disease, a groundbreaking development in biopharmaceuticals.
third-news.com
May 9, 2026 at 12:05 AM
newsen.bsky.social
Mabwell's Groundbreaking Anti-ST2 Monoclonal Antibody 9MW1911 Receives FDA IND Clearance for COPD Study#China#Shanghai#Mabwell #9MW1911#anti-ST2
Mabwell's Groundbreaking Anti-ST2 Monoclonal Antibody 9MW1911 Receives FDA IND Clearance for COPD Study
Mabwell has obtained FDA IND clearance for its innovative anti-ST2 monoclonal antibody 9MW1911, set to enter Phase IIa clinical trials for COPD.
third-news.com
December 24, 2025 at 2:13 PM
newsen.bsky.social
Mabwell's SynuSight Biotech Initiates Clinical Trials for Innovative α-syn PET Tracer#China#Shanghai#Mabwell#SynuSight#SST001
Mabwell's SynuSight Biotech Initiates Clinical Trials for Innovative α-syn PET Tracer
Mabwell's incubated firm, SynuSight Biotech, has secured NMPA approval to conduct Phase I trials for its promising α-syn PET tracer, SST001.
third-news.com
April 15, 2026 at 12:04 AM
newsen.bsky.social
Mabwell Showcases Promising Phase Ib/IIa Results of 9MW1911 for COPD at ERS 2026#China#Shanghai#Mabwell#COPD #9MW1911
Mabwell Showcases Promising Phase Ib/IIa Results of 9MW1911 for COPD at ERS 2026
Mabwell presents Phase Ib/IIa clinical data on its anti-ST2 monoclonal antibody 9MW1911 for COPD patients, demonstrating significant efficacy in reducing exacerbations.
third-news.com
September 4, 2026 at 1:09 PM
l2plabs.bsky.social
ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients
SHANGHAI, Sept. 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-ST2 monoclonal antibody 9MW1911 in patients with chronic obstructive...
dlvr.it
September 4, 2026 at 1:04 PM
newsen.bsky.social
Mabwell Achieves Second PIC/S GMP Certification through Successful Brazilian GMP Inspection#Denosumab#Mabwell#ANVISA
Mabwell Achieves Second PIC/S GMP Certification through Successful Brazilian GMP Inspection
Mabwell, a leading innovation-driven biopharmaceutical firm, successfully passes ANVISA's GMP inspection in Brazil, notching its second PIC/S certification.
third-news.com
August 10, 2026 at 12:05 AM
l2plabs.bsky.social
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site...
dlvr.it
August 10, 2026 at 12:02 AM
newsen.bsky.social
Mabwell to Unveil Breakthrough Clinical Data on 9MW2821 for Triple Negative Breast Cancer at ESMO 2026#ADC#Mabwell#Triple_Negative_Breast_Cancer
Mabwell to Unveil Breakthrough Clinical Data on 9MW2821 for Triple Negative Breast Cancer at ESMO 2026
Mabwell is set to present its latest findings on the ADC 9MW2821, targeting triple-negative breast cancer, at the ESMO 2026 in Madrid.
third-news.com
July 21, 2026 at 4:03 AM
biznizinsiderph.bsky.social
FDA IND approved: Mabwell’s first-in-class 9MW5211 moves forward in IBD and MS indications. Strong preclinical data behind it. Check the full article: aktiego.com/sectors/biot... #LifeSciences #BiotechStocks $MABWELL
Mabwell Receives FDA IND Clearance for Novel IBD Antibody 9MW5211 - AktieGo
Mabwell receives FDA IND clearance for 9MW5211 in IBD, a novel depleting antibody and the world's first clinical-stage drug candidate targeting its specific immune pathway.
aktiego.com
May 12, 2026 at 4:58 PM
pressreleasecc.com
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
www.pressreleasecc.com
May 17, 2026 at 12:45 PM